{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:50:00Z","timestamp":1787496600811,"version":"build-2736575974"},"reference-count":107,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and the fourth leading cause of cancer-related death globally. Tumor cells recruit and remodel various types of stromal and inflammatory cells to form a tumor microenvironment (TME), which encompasses cellular and molecular entities, including cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), immune cells, myeloid-derived suppressor cells (MDSCs), immune checkpoint molecules and cytokines that promote cancer cell growth, as well as their drug resistance. HCC usually arises in the context of cirrhosis, which is always associated with an enrichment of activated fibroblasts that are owed to chronic inflammation. CAFs are a major component of the TME, providing physical support in it and secreting various proteins, such as extracellular matrices (ECMs), hepatocyte growth factor (HGF), insulin-like growth factor 1\/2 (ILGF1\/2) and cytokines that can modulate tumor growth and survival. As such, CAF-derived signaling may increase the pool of resistant cells, thus reducing the duration of clinical responses and increasing the degree of heterogeneity within tumors. Although CAFs are often implicated to be associated with tumor growth, metastasis and drug resistance, several studies have reported that CAFs have significant phenotypic and functional heterogeneity, and some CAFs display antitumor and drug-sensitizing properties. Multiple studies have highlighted the relevance of crosstalk between HCC cells, CAFs and other stromal cells in influence of HCC progression. Although basic and clinical studies partially revealed the emerging roles of CAFs in immunotherapy resistance and immune evasion, a better understanding of the unique functions of CAFs in HCC progression will contribute to development of more effective molecular-targeted drugs. In this review article, molecular mechanisms involved in crosstalk between CAFs, HCC cells and other stromal cells, as well as the effects of CAFs on HCC-cell growth, metastasis, drug resistance and clinical outcomes, are comprehensively discussed.<\/jats:p>","DOI":"10.3390\/ijms24043941","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T02:04:03Z","timestamp":1676513043000},"page":"3941","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"24","author":[{"given":"Hikmet","family":"Akk\u0131z","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The University of Bah\u00e7e\u015fehir, Istanbul 34425, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.32355","article-title":"Declining disese burden of hepatocellular carcinomain the United States, 1992\u20132017: Apopulation-based analysis","volume":"76","author":"Han","year":"2022","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jhep.2022.01.018","article-title":"HCC surveillance improves early detection, curative treatment, and survival in patients with cirrhisis","volume":"77","author":"Zeng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design","volume":"77","author":"Allen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hep.32512","article-title":"Changing epidemiology of hepatocellular carcinoma in the United States: Winning the Battle but it is not over yet","volume":"76","author":"Khaderi","year":"2022","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis-novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_8","first-page":"1","article-title":"Hepatocellular Carcinoma","volume":"6","author":"Liovet","year":"2021","journal-title":"Nat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40364-022-00406-z","article-title":"Advances of cancer-associated fibroblasts in liver cancer","volume":"10","author":"Peng","year":"2022","journal-title":"Biomark. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eabj5879","DOI":"10.1126\/scisignal.abj5879","article-title":"IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells","volume":"15","author":"Rix","year":"2022","journal-title":"Sci. Signal"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.32447","article-title":"Emerging immunotherapy for HCC: A guide for hepatologists","volume":"75","author":"Foerster","year":"2022","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","volume":"76","author":"Tran","year":"2022","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblats and immune cells in the tumor microenvironment: New findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_16","first-page":"478","article-title":"Cancer-associated fibroblast-derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1\u03b1\/ZEB1 axis","volume":"13","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"ref_17","first-page":"174","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and Biology of Cancer-Associated Fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Baglieri, J., Brenner, D.A., and Kisseleva, T. (2019). The role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071723"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chung, J.Y.-F., Chan, M.K.-K., Li, J.S.-F., Chan, A.S.-W., Tang, P.C.-T., To, K.-F., Lan, H.-Y., and Tang, P.M.-K. (2021). TGF-\u03b2 Signaling: From Tissue Fibrosis to Tumor microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147575"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2016.05.022","article-title":"Cancer-associated fibroblasts promote hepatocellular metastasis through chemokine-activated hedgehog and TGF\u03b2 pathways","volume":"379","author":"Liu","year":"2016","journal-title":"Cancer Let."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ceb.2012.07.001","article-title":"Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche","volume":"24","author":"Brizzi","year":"2012","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1007\/s00018-015-1975-2","article-title":"Mesenchymal-epithelial interactions during digestive tract development and epithelial stem cell regeneration","volume":"72","author":"Marchal","year":"2015","journal-title":"Cell Mol. Life Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","article-title":"Tumor induction of VEGF promoter activity in stromal cells","volume":"94","author":"Fukumura","year":"1998","journal-title":"Cells"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.4049\/jimmunol.1402520","article-title":"Fibroblastic reticular cells: Organization and regulation of the T lymphocyte life cycle","volume":"194","author":"Brown","year":"2015","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.it.2010.11.002","article-title":"Lymph node stroma broaden the peripheral tolerance paradigm","volume":"32","author":"Fletcher","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.celrep.2016.04.019","article-title":"Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met\/FRA1\/HEY1 Signaling","volume":"15","author":"Lau","year":"2016","journal-title":"Cell Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.610513","article-title":"Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunothreapeuutically Relevant Subclasses","volume":"10","author":"Gao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.3389\/fimmu.2021.795372","article-title":"Emerging Role of Cancer-Associated Fibroblasts-Derived Exosomes in Tumorigenesis","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccr.2011.06.018","article-title":"ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma","volume":"20","author":"Gaggiolic","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ncomms10204","article-title":"Epigenetic switch drives the conversion of fibroblast into proinvasive cancer-associated fibroblasts","volume":"6","author":"Albrengues","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.celrep.2015.11.052","article-title":"Cdr42EP3BORG2 and septin network enables mechano-transduction and the emergence of cancer-associated fibroblasts","volume":"13","author":"Calvo","year":"2015","journal-title":"Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1101\/gad.304501.117","article-title":"Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics","volume":"31","author":"Foster","year":"2017","journal-title":"Genes. Dev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"613534","DOI":"10.3389\/fcell.2021.613534","article-title":"Cancer-associated Fibroblasts Suppress Cancer Development: The Other side of the Coin","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ncb3340","article-title":"Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis","volume":"18","author":"Nielsen","year":"2016","journal-title":"Nat. Cell. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2890","article-title":"Treatment-induced damage to the tumor microenvironment promote prostate cancer therapy resistance through WNT16B","volume":"18","author":"Sun","year":"2012","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"631931","DOI":"10.3389\/fcell.2021.631931","article-title":"Sulfatase 2-induced Cancer-Associated Fibroblasts Promote Hepatocellular Carcinoma Progression via Inhibition of Apoptosis and Induction of Epithelial-to-Mesenchymal Transition","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12061","DOI":"10.18632\/oncotarget.3616","article-title":"TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1\/CXCR4 signaling in hepatocellular carcinoma","volume":"6","author":"Song","year":"2015","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13578-020-00488-y","article-title":"Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.31848","article-title":"Perivenous Stellate Cells Are the Main Source of Myelofibroblasts Formed after Chronic liver injuries","volume":"74","author":"Wang","year":"2021","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e146987","DOI":"10.1172\/JCI146987","article-title":"Tumor restriction by type 1 collegene opposes tumor-promoting effects of cancer-associated fibroblasts","volume":"131","author":"Bhattacharjee","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/096368910X","article-title":"Mesenchymal stem cells","volume":"20","author":"Ding","year":"2011","journal-title":"Cell Transpl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-018-0926-6","article-title":"Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy","volume":"17","author":"Yin","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.matbio.2016.01.010","article-title":"Inflammation, fibrosis, and modulation of the process by mesenchymal stem\/stromal cells","volume":"51","author":"Prockop","year":"2016","journal-title":"Matrix Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"120168","DOI":"10.1016\/j.lfs.2021.120168","article-title":"Hepatocellular carcinoma cell line-microenvironment induced cancer-associated phenotype, genotype and functionality im mesenchymal stem cells","volume":"288","author":"Salah","year":"2022","journal-title":"Life Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/carcin\/bgr009","article-title":"Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis","volume":"32","author":"Bhattacharya","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.actbio.2018.07.001","article-title":"Cancer-derived exosomes trigger endothelial to mesenchymal transition followed by induction of cancer-associated fibroblasts","volume":"76","author":"Yeon","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_51","first-page":"6071","article-title":"Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin","volume":"40","author":"Greening","year":"2015","journal-title":"Cell. Dev. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"23337","DOI":"10.1074\/jbc.M700194200","article-title":"Fibroblasts Derive from Hepatocytes in Liver Fibrosis via Epithelial to Mesenchymal Transition","volume":"282","author":"Zeisberg","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/hep.23368","article-title":"Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice","volume":"51","author":"Taura","year":"2010","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.7150\/jca.25775","article-title":"The expression of FAP in hepatocellular carcinoma cells is induced by hypoxia and correlates with poor clinical outcomes","volume":"9","author":"Zou","year":"2018","journal-title":"J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Cathy, J.M., Gamarouidi, F.S., Lio, Z., and McManus, B.M. (2011). Wnt3a induces myofibroblasts differentiation by upregulating TGF-\u03b2 signaling through SMAD2 in a \u03b2-catenin-dependent manner. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019809"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tips.2012.03.013","article-title":"Liver X receptor biology and pharmacology: New pathways, challenges and opportunities","volume":"33","author":"Jakobson","year":"2012","journal-title":"Trend. Pharmacol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41389-019-0140-4","article-title":"LXR\u03b1 limits TGF\u03b2-dependent hepatocellular carcinoma associated fibroblast differentiation","volume":"36","author":"Moren","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100981","DOI":"10.1016\/j.tranon.2020.100981","article-title":"Integrative single-cell transcriptome analysis reveals a subpopulation of fibroblasts associated with favorable prognosis of liver cancer patients","volume":"14","author":"Wang","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1009789","DOI":"10.3389\/fimmu.2022.1009789","article-title":"Characterization of cancer-related fibroblasts (CAFs) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Qi, Y., Wang, H., Zhang, Q., Liu, Z., Wang, T., Wu, Z., and Wu, W. (2022). CAF-Released Exosomal miR-20-a-5p Facilities HCC Progression via the LIMA-1Mediated \u03b2-Catenin Pathway. Cells, 11.","DOI":"10.3390\/cells11233857"},{"key":"ref_64","first-page":"3536","article-title":"Impairment of a distinct cancer-associated fibroblast population limits tumor growth and metastasis","volume":"12","author":"Jangwirth","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20140692","article-title":"Fibroblast heterogeneity in the cancer wound","volume":"211","author":"Ohlund","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Ohlund","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","article-title":"Phenotype molding of stromal cells in the lung tumor microenvironment","volume":"24","author":"Lambrechts","year":"2018","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41388-021-02171-z","article-title":"Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma","volume":"41","author":"Chiavarina","year":"2022","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/hep.31792","article-title":"Cancer-Associated Fibroblasts-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.24485","article-title":"Tumor-secreted Lysophostatidic Acid Accelerates Hepatocellular Carcinoma Progression by Promoting Differentiation of Peritumoral Fibroblasts in Myofibrolbasts","volume":"54","author":"Mazzocca","year":"2011","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.31768","article-title":"Cancer-Associated Fibroblasts: Orchestrating the Crosstalk Between Liver Cancer Cells and Neutrophils Through the Cardiotrophin-Like Cytokine Factor1-Mediated Chemokine (C-X-C motif) Ligand 6\/TGF-\u03b2 Axis","volume":"5","author":"Lei","year":"2021","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1158\/0008-5472.CAN-17-0988","article-title":"Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1\/2-AP1 and SP1 Axis","volume":"78","author":"Rhee","year":"2018","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-019-0782-x","article-title":"Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma","volume":"12","author":"Yin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2017.03.004","article-title":"Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis","volume":"397","author":"Zhang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1101\/gad.279737.116","article-title":"Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy","volume":"30","author":"Gascard","year":"2016","journal-title":"Genes Dev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The Role of Cancer-Associated Fibroblasts and Fibrosisin liver Cancer","volume":"12","author":"Affo","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"ref_77","first-page":"472","article-title":"Modulating the tumor-associated macropahge landscape","volume":"23","author":"Boissonnas","year":"2022","journal-title":"Nat. Cancer Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.biopha.2012.02.001","article-title":"Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related promotion of cancer progression in hepatocellular carcinoma cells","volume":"66","author":"Lin","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature06188","article-title":"Mesenchymal stem cells within tumor stroma promote breast cancer metastasis","volume":"449","author":"Kamoub","year":"2007","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: An emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hemotol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2021.5239","article-title":"Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibit\u00f6r-1 pathway","volume":"59","author":"Chen","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-19-2691","article-title":"Interaction with CD68 and regulation of GAS6 Expression by Endosialin in Fibroblasts Drives Recruitment and Polarization of Macrophages in Hepatocellular Carcinoma","volume":"80","author":"Yang","year":"2020","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41419-018-0458-4","article-title":"Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL-6\/STAT3 pathway that foster immune suppression in hepatocellular carcinoma","volume":"9","author":"Cheng","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.31416","article-title":"Liver Cancer Immunity","volume":"73","author":"Rizvi","year":"2021","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","article-title":"From bench to bed: The tumor immune microenvironment and current immunotherapeutic strategies fro hepatocellular carcinoma","volume":"38","author":"Fu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastronterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1073\/pnas.1818210116","article-title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","volume":"116","author":"Miranda","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Arvanitakis, K., Mitroulis, I., and Germanidis, G. (2021). Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy. Cancers, 13.","DOI":"10.3390\/cancers13122899"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13046-015-0256-0","article-title":"Peritumoral neutrophils negatively regulate adaptive immunity via the PD-L1\/PD-1 signaling pathway in hepatocellular carcinoma","volume":"34","author":"He","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a Mouse model of pancreatic cancer","volume":"62","author":"Jakobetz","year":"2013","journal-title":"Gut"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"E309I","DOI":"10.1073\/pnas.1411679111","article-title":"Stromal response to Hedgehog signaling restrains pancreatic cancer progression","volume":"111","author":"Lee","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a Mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: Randomised phase II study of PEGPH20 plus Nab-Paclitaxel \/Gemcitabine in patients with untreated, metastatic, pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/JCO.2020.38.4_suppl.638","article-title":"HALO 301: A randomized, double-blind, placebo-controlled phase 3 study of pegvorhya luronidase alpha (PEGPH20) + nab-paclitoxel\/gemcitabine (AG) in patients with with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA)","volume":"38","author":"Tempero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_100","unstructured":"US National library of Medicine (2022, November 25). Clinical Trials gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01585701."},{"key":"ref_101","unstructured":"US National library of Medicine (2022, November 25). Clinical Trials gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/Show\/NCT011951690."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1073\/pnas.1300415110","article-title":"CTGF antogonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murin ductal pancreas cancer","volume":"110","author":"Neesse","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","unstructured":"US National Library of Medicine (2022, November 25). Clinical Trials gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NTC03386721."},{"key":"ref_104","unstructured":"National Library of Medicine (2022, November 25). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02688712."},{"key":"ref_105","unstructured":"US National Library of Medicine (2022, November 25). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03563248."},{"key":"ref_106","unstructured":"US National Library of Medicine (2022, November 25). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01472198."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"North, B., Kocher, H.M., and Sasieni, P. (2019). A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5801-3"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3941\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:37:01Z","timestamp":1760121421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":107,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043941"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043941","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}